Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 36 studies | 33% ± 13% | |
macrophage | 21 studies | 26% ± 13% | |
fibroblast | 16 studies | 31% ± 11% | |
ciliated cell | 15 studies | 39% ± 16% | |
classical monocyte | 15 studies | 26% ± 8% | |
smooth muscle cell | 12 studies | 26% ± 8% | |
pericyte | 12 studies | 28% ± 11% | |
endothelial cell of vascular tree | 12 studies | 34% ± 19% | |
endothelial cell of lymphatic vessel | 11 studies | 34% ± 18% | |
non-classical monocyte | 11 studies | 24% ± 7% | |
astrocyte | 11 studies | 31% ± 14% | |
monocyte | 10 studies | 33% ± 12% | |
microglial cell | 10 studies | 32% ± 12% | |
oligodendrocyte | 10 studies | 26% ± 9% | |
basal cell | 9 studies | 23% ± 11% | |
adipocyte | 9 studies | 41% ± 16% | |
vein endothelial cell | 9 studies | 42% ± 23% | |
myeloid cell | 8 studies | 32% ± 8% | |
type I pneumocyte | 7 studies | 25% ± 6% | |
GABAergic neuron | 7 studies | 34% ± 20% | |
dendritic cell | 7 studies | 27% ± 8% | |
endothelial cell of artery | 7 studies | 25% ± 6% | |
epithelial cell | 6 studies | 40% ± 11% | |
capillary endothelial cell | 6 studies | 28% ± 10% | |
type II pneumocyte | 6 studies | 27% ± 6% | |
oligodendrocyte precursor cell | 6 studies | 27% ± 12% | |
cardiac muscle cell | 5 studies | 48% ± 11% | |
club cell | 5 studies | 23% ± 5% | |
retinal pigment epithelial cell | 4 studies | 29% ± 15% | |
mononuclear phagocyte | 4 studies | 29% ± 7% | |
lymphocyte | 4 studies | 26% ± 6% | |
glutamatergic neuron | 4 studies | 55% ± 19% | |
interneuron | 4 studies | 39% ± 23% | |
natural killer cell | 3 studies | 18% ± 1% | |
hematopoietic precursor cell | 3 studies | 26% ± 6% | |
mesothelial cell | 3 studies | 29% ± 8% | |
hepatocyte | 3 studies | 45% ± 31% | |
connective tissue cell | 3 studies | 24% ± 8% | |
ependymal cell | 3 studies | 59% ± 5% | |
neutrophil | 3 studies | 18% ± 2% | |
adventitial cell | 3 studies | 25% ± 8% | |
T cell | 3 studies | 20% ± 2% | |
alveolar macrophage | 3 studies | 35% ± 11% | |
Schwann cell | 3 studies | 36% ± 16% | |
goblet cell | 3 studies | 32% ± 23% | |
transit amplifying cell | 3 studies | 29% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 9621.33 | 1444 / 1445 | 100% | 64.27 | 183 / 183 |
thymus | 100% | 11416.98 | 652 / 653 | 100% | 53.65 | 604 / 605 |
lung | 99% | 8894.02 | 575 / 578 | 100% | 44.14 | 1155 / 1155 |
breast | 100% | 13312.17 | 459 / 459 | 99% | 54.46 | 1112 / 1118 |
prostate | 100% | 6816.77 | 244 / 245 | 100% | 42.20 | 501 / 502 |
ovary | 100% | 8080.39 | 180 / 180 | 99% | 32.33 | 427 / 430 |
kidney | 100% | 4898.28 | 89 / 89 | 99% | 50.10 | 891 / 901 |
uterus | 100% | 11160.42 | 170 / 170 | 98% | 32.87 | 452 / 459 |
intestine | 100% | 8971.47 | 965 / 966 | 98% | 29.96 | 514 / 527 |
stomach | 99% | 6829.72 | 356 / 359 | 97% | 37.85 | 278 / 286 |
bladder | 100% | 9393.00 | 21 / 21 | 96% | 26.06 | 482 / 504 |
adrenal gland | 100% | 5049.29 | 258 / 258 | 93% | 31.42 | 213 / 230 |
skin | 100% | 6988.39 | 1808 / 1809 | 91% | 29.04 | 430 / 472 |
brain | 91% | 3085.09 | 2406 / 2642 | 100% | 28.47 | 704 / 705 |
pancreas | 92% | 3252.69 | 301 / 328 | 99% | 37.69 | 176 / 178 |
liver | 93% | 3276.42 | 210 / 226 | 87% | 17.83 | 352 / 406 |
adipose | 100% | 16501.88 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 11161.62 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 11322.92 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5763.08 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 36.67 | 45 / 45 |
heart | 97% | 8086.56 | 839 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 24.64 | 28 / 29 |
peripheral blood | 76% | 4448.78 | 705 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 66% | 13.29 | 53 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0006468 | Biological process | protein phosphorylation |
GO_0009299 | Biological process | mRNA transcription |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0043508 | Biological process | negative regulation of JUN kinase activity |
GO_0016604 | Cellular component | nuclear body |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0004672 | Molecular function | protein kinase activity |
Gene name | HIPK3 |
Protein name | Homeodomain-interacting protein kinase 3 (EC 2.7.11.1) (Androgen receptor-interacting nuclear protein kinase) (ANPK) (Fas-interacting serine/threonine-protein kinase) (FIST) (Homolog of protein kinase YAK1) Homeodomain interacting protein kinase 3 |
Synonyms | PKY FIST3 DYRK6 |
Description | FUNCTION: Serine/threonine-protein kinase involved in transcription regulation, apoptosis and steroidogenic gene expression. Phosphorylates JUN and RUNX2. Seems to negatively regulate apoptosis by promoting FADD phosphorylation. Enhances androgen receptor-mediated transcription. May act as a transcriptional corepressor for NK homeodomain transcription factors. The phosphorylation of NR5A1 activates SF1 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. In osteoblasts, supports transcription activation: phosphorylates RUNX2 that synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). . |
Accessions | ENST00000379016.7 [Q9H422-2] ENST00000303296.9 [Q9H422-1] Q9H422 ENST00000456517.2 [Q9H422-2] ENST00000531504.5 E9PKD7 ENST00000525975.5 [Q9H422-2] |